newsfilter
← Latest News
Business Wire·

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

License agreement also grants Glaukos exclusive rights to the RevMod™ platform for the discovery and development of up to four additional next-generation biologics for various retinal diseases Glaukos Corporation